{"product_id":"macrogenics-swot-analysis","title":"MacroGenics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMacroGenics is navigating a dynamic biotech landscape, leveraging its innovative DART platform to develop promising oncology and autoimmune therapies. However, the company faces significant competition and the inherent risks of drug development. \u003c\/p\u003e\n\u003cp\u003eWant the full story behind MacroGenics' strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary DART and TRIDENT Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics' proprietary DART and TRIDENT platforms are a significant strength, enabling the creation of antibodies that target multiple antigens simultaneously. This dual-affinity re-targeting technology allows for more precise engagement with disease cells, potentially leading to greater therapeutic effectiveness and fewer off-target effects compared to single-target antibodies.\u003c\/p\u003e\n\u003cp\u003eThese innovative platforms offer a distinct advantage in drug development by streamlining the manufacturing process and potentially reducing clinical trial complexity. By engineering antibodies to perform multiple functions, MacroGenics can develop more potent and efficient treatments for a range of diseases, setting them apart in the competitive biopharmaceutical landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Clinical Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics boasts a strong and varied pipeline of drug candidates, with a particular emphasis on cancer treatments. This includes promising bispecific antibodies and advanced antibody-drug conjugates designed to target different types of cancer.\u003c\/p\u003e\n\u003cp\u003eKey assets in their oncology portfolio include lorigerlimab, a dual-action molecule targeting PD-1 and CTLA-4, and several next-generation ADCs like MGC026, MGC028, and MGC030, which feature innovative payloads. This extensive range demonstrates a strategic focus on developing novel therapies for unmet medical needs in oncology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics has forged significant strategic collaborations with industry leaders such as Incyte, Gilead, and Sanofi. These partnerships are a cornerstone of their strategy, providing substantial non-dilutive capital through upfront payments and development milestones.\u003c\/p\u003e\n\u003cp\u003eThe financial benefits from these collaborations are considerable, with potential for future royalties further enhancing their revenue streams. For instance, the collaboration with Incyte for retifanlimab has already yielded upfront and milestone payments, demonstrating the tangible financial impact of these alliances.\u003c\/p\u003e\n\u003cp\u003eThese agreements are instrumental in de-risking the substantial costs associated with drug development and significantly accelerate the path to potential market approval and commercialization for MacroGenics' innovative therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtended Cash Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics' extended cash runway is a significant strength, bolstered by strategic financial maneuvers. A key element was the royalty purchase agreement for ZYNYZ with Sagard Healthcare Partners, alongside substantial milestone payments from collaborations. \u003c\/p\u003e\n\u003cp\u003eAs of June 30, 2025, the company projected its cash runway to extend into the first half of 2027. This robust financial position offers crucial flexibility for pipeline advancement and strategic execution without immediate pressure for equity financing. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrengthened Liquidity:\u003c\/strong\u003e Achieved through a royalty purchase agreement for ZYNYZ and significant milestone payments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExtended Cash Runway:\u003c\/strong\u003e Projected to last through the first half of 2027 as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Flexibility:\u003c\/strong\u003e Enables pipeline progression and initiative execution without immediate dilution concerns.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpertise in Antibody Engineering and Disease Biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics boasts significant strengths in antibody engineering and a deep understanding of disease biology, particularly immune-mediated mechanisms. This expertise enables them to craft highly specific antibody-based therapies.  For instance, their ability to integrate third-party proprietary linker payloads into Antibody-Drug Conjugates (ADCs) showcases this technical prowess.  This foundational strength is crucial for developing novel treatments that improve upon current standards of care.\u003c\/p\u003e\n\u003cp\u003eThis scientific acumen translates into a robust pipeline. In 2024, MacroGenics continued to advance its investigational therapies, with a focus on oncology and autoimmune diseases. Their platform technology allows for the creation of differentiated molecules, targeting specific disease pathways with greater precision.  The company's commitment to innovation in this area is a key differentiator in the competitive biopharmaceutical landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: Tech, Pipeline, Partnerships, and Strong Financials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' proprietary DART and TRIDENT platforms are a significant strength, enabling the creation of antibodies that target multiple antigens simultaneously. This dual-affinity re-targeting technology allows for more precise engagement with disease cells, potentially leading to greater therapeutic effectiveness and fewer off-target effects compared to single-target antibodies.\u003c\/p\u003e\n\u003cp\u003eMacroGenics boasts a strong and varied pipeline of drug candidates, with a particular emphasis on cancer treatments. Key assets in their oncology portfolio include lorigerlimab, a dual-action molecule targeting PD-1 and CTLA-4, and several next-generation ADCs like MGC026, MGC028, and MGC030, which feature innovative payloads. This extensive range demonstrates a strategic focus on developing novel therapies for unmet medical needs in oncology.\u003c\/p\u003e\n\u003cp\u003eMacroGenics has forged significant strategic collaborations with industry leaders such as Incyte, Gilead, and Sanofi. These partnerships are a cornerstone of their strategy, providing substantial non-dilutive capital through upfront payments and development milestones, with potential for future royalties further enhancing their revenue streams. These agreements are instrumental in de-risking the substantial costs associated with drug development and significantly accelerate the path to potential market approval and commercialization.\u003c\/p\u003e\n\u003cp\u003eMacroGenics' extended cash runway is a significant strength, bolstered by strategic financial maneuvers. As of June 30, 2025, the company projected its cash runway to extend into the first half of 2027, offering crucial flexibility for pipeline advancement and strategic execution without immediate pressure for equity financing.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of MacroGenics’s internal and external business factors, highlighting its product pipeline, market position, and competitive landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eMacroGenics' SWOT analysis provides a clear, actionable roadmap by highlighting internal strengths and weaknesses alongside external opportunities and threats, enabling targeted strategies to overcome market challenges and capitalize on growth potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependency on R\u0026amp;D Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics' financial health and market standing are deeply tied to the success of its research and development pipeline. The company's valuation hinges on positive results from its ongoing preclinical and clinical trials.\u003c\/p\u003e\n\u003cp\u003eThe unpredictable nature of drug development means that any negative or inconclusive trial outcomes for its lead candidates, such as those for tebentafusp in certain indications, could cause significant stock price fluctuations and derail future growth plans.\u003c\/p\u003e\n\u003cp\u003eThis heavy reliance on R\u0026amp;D success exposes MacroGenics to a heightened risk of clinical trial failures, which can have a substantial impact on its financial trajectory and investor confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Commercialized Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics' commercialized product portfolio is quite narrow, which presents a significant weakness. The sale of its product MARGENZA in November 2024 further illustrates this, fundamentally altering its revenue streams from direct product sales to a greater reliance on other income sources.\u003c\/p\u003e\n\u003cp\u003eThis shift means MacroGenics now depends more heavily on collaboration income, milestone payments from partnerships, and revenue generated from contract manufacturing services. This dependence can introduce volatility and unpredictability into its financial performance, as these income streams are not always guaranteed or consistent.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Setbacks and Safety Concerns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics has encountered substantial hurdles in its clinical development pipeline. A notable setback occurred in early 2024 with the discontinuation of internal development for vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer, a decision driven by trial results that did not justify continued financial commitment.\u003c\/p\u003e\n\u003cp\u003eThese clinical challenges are compounded by prior safety concerns. The TAMARACK study, for instance, reported patient deaths in 2024, underscoring the significant risks inherent in advancing novel oncology treatments through rigorous testing phases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Volatility and Persistent Net Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics has grappled with persistent net losses, a significant weakness in its financial profile. For instance, in the first quarter of 2024, the company reported a net loss of $35.1 million, a continuation of its historical trend. This ongoing financial instability, coupled with considerable stock price volatility within the often-unpredictable biotech sector, raises concerns for investors about the company's long-term viability and its ability to achieve consistent profitability.\u003c\/p\u003e\n\u003cp\u003eDespite efforts to manage its cash burn, such as extending cash runway through strategic financing and operational adjustments, MacroGenics still faces substantial financial hurdles. The company's ability to generate sustainable revenue and transition to profitability remains a critical challenge. As of the first quarter of 2024, MacroGenics had $173.5 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2025, but this doesn't negate the fundamental need for improved financial performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePersistent Net Losses:\u003c\/strong\u003e MacroGenics has consistently reported net losses, impacting its financial stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStock Volatility:\u003c\/strong\u003e The company's stock price has experienced significant fluctuations, reflecting market concerns in the biotech industry.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeed for Profitability:\u003c\/strong\u003e Achieving consistent profitability remains a key challenge and a major concern for investors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Runway:\u003c\/strong\u003e While cash reserves provide a runway, the company must demonstrate a clear path to financial self-sufficiency.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe oncology sector, especially immunotherapeutics, is incredibly crowded. MacroGenics faces stiff competition not only from established pharmaceutical giants with deep pockets but also from nimble, well-funded biotech startups. This intense rivalry means MacroGenics' novel treatments must constantly battle for attention and market share against a wave of existing and emerging therapies, making commercial success a significant hurdle.\u003c\/p\u003e\n\u003cp\u003eThe biopharmaceutical industry's oncology segment is a battleground, with numerous players vying for dominance. For instance, in 2024, the global oncology market was valued at approximately $200 billion, projected to grow substantially. MacroGenics' innovative approaches, while promising, must contend with a landscape populated by companies like Pfizer, Merck, and Bristol Myers Squibb, each with extensive oncology portfolios and significant marketing power. This environment necessitates continuous innovation and effective market penetration strategies to stand out.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Barrier to Entry:\u003c\/strong\u003e The significant capital investment required for drug development and commercialization creates a high barrier to entry for smaller players.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEstablished Players:\u003c\/strong\u003e Large pharmaceutical companies have existing infrastructure, sales forces, and brand recognition that are difficult for emerging biotechs to overcome.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRapid Scientific Advancements:\u003c\/strong\u003e The field is constantly evolving with new discoveries and treatment modalities, requiring companies like MacroGenics to stay at the forefront of research and development to remain competitive.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Volatility and Pipeline Setbacks Challenge Viability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' reliance on a narrow product portfolio, exacerbated by the sale of MARGENZA in late 2024, shifts its revenue streams significantly towards less predictable income sources like collaboration payments and milestone receipts. This dependence introduces financial volatility, as these income streams are not guaranteed. Furthermore, the company has faced substantial setbacks in its development pipeline, including the discontinuation of vobramitamab duocarmazine in early 2024 due to unfavorable trial results, and prior safety concerns highlighted by patient deaths in the TAMARACK study in 2024. These clinical challenges, coupled with persistent net losses, such as the $35.1 million loss in Q1 2024, and significant stock price volatility, raise questions about long-term financial viability and the ability to achieve consistent profitability, despite a cash runway extending into the latter half of 2025.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMacroGenics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real document you'll receive—professional, structured, and ready to use. You'll gain a comprehensive understanding of MacroGenics' Strengths, Weaknesses, Opportunities, and Threats. The full, detailed analysis is immediately accessible upon purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55673892340089,"sku":"macrogenics-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/macrogenics-swot-analysis.png?v=1755784443","url":"https:\/\/portersfiveforce.com\/products\/macrogenics-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}